Summary
AbbVie Inc. (ABBV) filed an 8-K report on April 2, 2025, providing a preliminary update on its first quarter 2025 financial performance. The company expects to incur approximately $248 million in acquired In-Process Research & Development (IPR&D) and milestones expense on a pre-tax basis during the first quarter. This expense is estimated to have an unfavorable impact of $0.13 on both GAAP and adjusted non-GAAP diluted earnings per share (EPS). While this expense was not previously forecasted in the company's initial 2025 guidance, AbbVie has updated its full-year 2025 adjusted diluted EPS guidance to a range of $11.99 - $12.19. The updated first quarter 2025 adjusted diluted EPS guidance is now $2.34 - $2.38. Investors should note that this guidance does not include the impact of the licensing agreement with Gubra for GUB014295, as that transaction closed after the first quarter. The company emphasizes that these are preliminary estimates and actual results are subject to finalization.
Key Highlights
- 1AbbVie anticipates $248 million in pre-tax acquired IPR&D and milestones expense for Q1 2025.
- 2This expense is projected to negatively impact Q1 GAAP and adjusted non-GAAP EPS by $0.13.
- 3Full-year 2025 adjusted diluted EPS guidance is revised to $11.99 - $12.19.
- 4Q1 2025 adjusted diluted EPS guidance is updated to $2.34 - $2.38.
- 5Guidance excludes the impact of the recent Gubra licensing agreement for GUB014295, which closed post-Q1.
- 6The reported figures are preliminary estimates and subject to change upon final financial statement closing.
- 7AbbVie does not typically forecast acquired IPR&D and milestones expenses due to inherent uncertainty.